{"success":true,"data":{"pressRelease":{"id":"42297","rtpr_id":"nPn9SkQmVa","ticker":"RGC","exchange":"NASDAQ","all_tickers":["RGC"],"title":"Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt","author":"PR Newswire","published_at":"2026-05-21T13:00:05.533Z","article_body":"Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, May 21, 2026\n\nAlert: Regencell's $14 Billion Market Valuation Built on Zero Revenue\nCollapsed 18.56% After DOJ Subpoena Revealed Alleged Market Manipulation\nInvestigation\n\nNEW YORK, May 21, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegencell Bioscience Holdings Limited (NASDAQ: RGC) that a class action\nlawsuit has been filed on behalf of shareholders who purchased securities\nbetween October 28, 2024 and October 31, 2025. Find out if you qualify to\nrecover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=654036775&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nRGC shares fell $3.09 per share, or 18.56%, closing at $13.56 on November 3,\n2025, after the Company disclosed a U.S. Department of Justice subpoena\ninvestigating trading in its ordinary shares. The lead plaintiff deadline is\nJune 23, 2026.\n\nA $14 Billion Valuation Untethered From Economic Reality\n\nRegencell achieved a market capitalization of approximately $14 billion\ndespite operating with twelve employees, generating zero revenue, and spending\nroughly $1 million annually on research and development. The Wall Street\nJournal noted in January 2026 that only 20 of the 261 companies in the Nasdaq\nBiotechnology Index carried a greater market value. The lawsuit contends that\nthis extraordinary valuation disconnect was fueled by trading activity\nunrelated to business fundamentals, and that Defendants knew or recklessly\ndisregarded the manipulation vulnerability that inflated share prices.\n\nThe 48,650% Surge and Subsequent Unraveling\n\nThe complaint chronicles an extraordinary price trajectory:\n\n * From the start of the Class Period through mid-March 2025, RGC shares traded\nbelow $0.30 per share\n * By May 1, 2025, shares suddenly closed at $2.03, with no corresponding Company\nnews\n * On June 17, 2025, shares reached a Class Period high of $78.00, representing a\n48,650% increase from the Class Period start\n * Within one week of the peak, shares collapsed to slightly above $20.00\n * On November 3, 2025, following the DOJ subpoena disclosure, shares fell an\nadditional 18.56% to $13.56\nThe filing states that throughout these swings, Defendants attributed\nvolatility to short-selling activity and third-party social media commentary\nrather than disclosing the Company's vulnerability to market manipulation or\nthe regulatory scrutiny that vulnerability invited.\n\nWhat the Corrective Disclosure Revealed About Market Risk\n\nOn October 31, 2025, Regencell disclosed in its annual report that it had\nreceived correspondence and a subpoena from the DOJ \"indicating that the DOJ\nis conducting an investigation into the trading in our Ordinary Shares.\" The\nCompany acknowledged the DOJ requested documents concerning \"corporate\noperational, financial and accounting matters\" and warned it \"may be required\nto pay fines, penalties, damages or settlement costs in excess of our\ninsurance coverage.\"\n\nThe action asserts that this disclosure contradicted months of filings that\nframed volatility risks in generic, hypothetical terms while concealing that\nmanipulation-driven trading had already attracted federal law enforcement\nattention.\n\nSee if you can recover losses from the RGC stock decline\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=2587599277&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=See+if+you+can+recover+losses+from+the+RGC+stock+decline)\n or call (888) SueWallSt.\n\n\"When companies fail to disclose material information, shareholders may suffer\nsignificant losses. The disparity between Regencell's market valuation and its\nunderlying business fundamentals raises important questions about the adequacy\nof its risk disclosures during a period of extraordinary trading\nactivity.\" -- Joseph E. Levi, Esq.\n\nJoin the Regencell Bioscience recovery action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=184776660&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=Join+the+Regencell+Bioscience+recovery+action)\n or contact Joseph E. Levi, Esq. at (888) SueWallSt.\n\nABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of\nmillions of dollars for aggrieved shareholders. The firm has extensive\nexpertise in complex securities litigation and a team of over 70 employees.\nFor seven consecutive years, SueWallSt has ranked in ISS Securities Class\nAction Services' Top 50 Report. To be considered for lead plaintiff, investors\nmust file by June 23, 2026.\n\nFrequently Asked Questions About the RGC Lawsuit\n\nQ: When did Regencell Bioscience allegedly mislead investors? A: The class\nperiod runs from October 28, 2024 to October 31, 2025. The alleged fraud was\nrevealed through a corrective disclosure on October 31, 2025, when Regencell\ndisclosed the DOJ subpoena, causing shares to decline 18.56%.\n\nQ: How much did RGC stock drop? A: Shares fell $3.09 per share, or 18.56%,\nclosing at $13.56 on November 3, 2025, after the Company disclosed it had\nreceived a subpoena from the U.S. Department of Justice regarding an\ninvestigation into the trading of its ordinary shares.\n\nQ: What do RGC investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my RGC shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lost-money-on-regencell-bioscience-holdings-limited-rgc-join-class-action-suit-seeking-recovery---contact-suewallst-302778427.html\n(https://www.prnewswire.com/news-releases/lost-money-on-regencell-bioscience-holdings-limited-rgc-join-class-action-suit-seeking-recovery---contact-suewallst-302778427.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9SkQmVa","title":"Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt","author":"PR Newswire","ticker":"RGC","created":"2026-05-21T13:00:05.533Z","tickers":["RGC"],"exchange":"NASDAQ","article_body":"Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt\n\nPR Newswire\n\nNEW YORK, May 21, 2026\n\nAlert: Regencell's $14 Billion Market Valuation Built on Zero Revenue\nCollapsed 18.56% After DOJ Subpoena Revealed Alleged Market Manipulation\nInvestigation\n\nNEW YORK, May 21, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegencell Bioscience Holdings Limited (NASDAQ: RGC) that a class action\nlawsuit has been filed on behalf of shareholders who purchased securities\nbetween October 28, 2024 and October 31, 2025. Find out if you qualify to\nrecover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=654036775&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=Find+out+if+you+qualify+to+recover+losses)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nRGC shares fell $3.09 per share, or 18.56%, closing at $13.56 on November 3,\n2025, after the Company disclosed a U.S. Department of Justice subpoena\ninvestigating trading in its ordinary shares. The lead plaintiff deadline is\nJune 23, 2026.\n\nA $14 Billion Valuation Untethered From Economic Reality\n\nRegencell achieved a market capitalization of approximately $14 billion\ndespite operating with twelve employees, generating zero revenue, and spending\nroughly $1 million annually on research and development. The Wall Street\nJournal noted in January 2026 that only 20 of the 261 companies in the Nasdaq\nBiotechnology Index carried a greater market value. The lawsuit contends that\nthis extraordinary valuation disconnect was fueled by trading activity\nunrelated to business fundamentals, and that Defendants knew or recklessly\ndisregarded the manipulation vulnerability that inflated share prices.\n\nThe 48,650% Surge and Subsequent Unraveling\n\nThe complaint chronicles an extraordinary price trajectory:\n\n * From the start of the Class Period through mid-March 2025, RGC shares traded\nbelow $0.30 per share\n * By May 1, 2025, shares suddenly closed at $2.03, with no corresponding Company\nnews\n * On June 17, 2025, shares reached a Class Period high of $78.00, representing a\n48,650% increase from the Class Period start\n * Within one week of the peak, shares collapsed to slightly above $20.00\n * On November 3, 2025, following the DOJ subpoena disclosure, shares fell an\nadditional 18.56% to $13.56\nThe filing states that throughout these swings, Defendants attributed\nvolatility to short-selling activity and third-party social media commentary\nrather than disclosing the Company's vulnerability to market manipulation or\nthe regulatory scrutiny that vulnerability invited.\n\nWhat the Corrective Disclosure Revealed About Market Risk\n\nOn October 31, 2025, Regencell disclosed in its annual report that it had\nreceived correspondence and a subpoena from the DOJ \"indicating that the DOJ\nis conducting an investigation into the trading in our Ordinary Shares.\" The\nCompany acknowledged the DOJ requested documents concerning \"corporate\noperational, financial and accounting matters\" and warned it \"may be required\nto pay fines, penalties, damages or settlement costs in excess of our\ninsurance coverage.\"\n\nThe action asserts that this disclosure contradicted months of filings that\nframed volatility risks in generic, hypothetical terms while concealing that\nmanipulation-driven trading had already attracted federal law enforcement\nattention.\n\nSee if you can recover losses from the RGC stock decline\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=2587599277&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=See+if+you+can+recover+losses+from+the+RGC+stock+decline)\n or call (888) SueWallSt.\n\n\"When companies fail to disclose material information, shareholders may suffer\nsignificant losses. The disparity between Regencell's market valuation and its\nunderlying business fundamentals raises important questions about the adequacy\nof its risk disclosures during a period of extraordinary trading\nactivity.\" -- Joseph E. Levi, Esq.\n\nJoin the Regencell Bioscience recovery action\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4693501-15&h=184776660&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregencell-bioscience-holdings-limited-class-action-lawsuit-rgc%3Fprid%3D186076%26wire%3D4&a=Join+the+Regencell+Bioscience+recovery+action)\n or contact Joseph E. Levi, Esq. at (888) SueWallSt.\n\nABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of\nmillions of dollars for aggrieved shareholders. The firm has extensive\nexpertise in complex securities litigation and a team of over 70 employees.\nFor seven consecutive years, SueWallSt has ranked in ISS Securities Class\nAction Services' Top 50 Report. To be considered for lead plaintiff, investors\nmust file by June 23, 2026.\n\nFrequently Asked Questions About the RGC Lawsuit\n\nQ: When did Regencell Bioscience allegedly mislead investors? A: The class\nperiod runs from October 28, 2024 to October 31, 2025. The alleged fraud was\nrevealed through a corrective disclosure on October 31, 2025, when Regencell\ndisclosed the DOJ subpoena, causing shares to decline 18.56%.\n\nQ: How much did RGC stock drop? A: Shares fell $3.09 per share, or 18.56%,\nclosing at $13.56 on November 3, 2025, after the Company disclosed it had\nreceived a subpoena from the U.S. Department of Justice regarding an\ninvestigation into the trading of its ordinary shares.\n\nQ: What do RGC investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt. No immediate action is\nrequired to remain eligible as a class member.\n\nQ: What if I already sold my RGC shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/lost-money-on-regencell-bioscience-holdings-limited-rgc-join-class-action-suit-seeking-recovery---contact-suewallst-302778427.html\n(https://www.prnewswire.com/news-releases/lost-money-on-regencell-bioscience-holdings-limited-rgc-join-class-action-suit-seeking-recovery---contact-suewallst-302778427.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-21T13:00:05.551443591Z","server_sent_at_ms":1779368405551},"received_at":"2026-05-21T13:00:05.738Z","source_url":"https://www.prnewswire.com/news-releases/lost-money-on-regencell-bioscience-holdings-limited-rgc-join-class-action-suit-seeking-recovery---contact-suewallst-302778427.html"},"analysis":{"id":"31738","press_release_id":"42297","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Plaintiff law-firm solicitation (low signal)","Zero revenue company with $14B market cap","DOJ subpoena for trading investigation"],"eventType":"legal_litigation","narrative":"SueWallSt (Levi & Korsinsky) issued a press release soliciting shareholders of Regencell Bioscience Holdings (RGC) to join a class action lawsuit.\n\nThe firm alleges that RGC's $14 billion market valuation was inflated by undisclosed market manipulation, despite the company having zero revenue and only 12 employees.\n\nThe release highlights a DOJ subpoena regarding trading activity and a subsequent 18.56% stock drop, urging investors to contact the firm by the June 23, 2026 lead plaintiff deadline.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Suppress: Routine plaintiff-firm solicitation for RGC class action."},"keyFigures":{"customDimensions":{"surge_pct":"48,650%","market_cap":"$14 billion","employee_count":12,"price_drop_pct":"18.56%","price_drop_usd":"$3.09","rd_spend_annual":"$1 million","share_price_peak":"$78.00","share_price_close":"$13.56"}},"quotedText":"When companies fail to disclose material information, shareholders may suffer significant losses. The disparity between Regencell's market valuation and its underlying business fundamentals raises important questions about the adequacy of its risk disclosures during a period of extraordinary trading activity.","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at Levi & Korsinsky"}],"products":[],"companies":[{"name":"Regencell Bioscience Holdings Limited","ticker":"RGC","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"U.S. Department of Justice","relationship":"regulator"}],"dollarAmounts":[{"amount":"$14 billion","context":"market capitalization"},{"amount":"$1 million","context":"annual R&D spend"},{"amount":"$3.09","context":"share price drop"},{"amount":"$13.56","context":"closing share price"},{"amount":"$0.30","context":"pre-surge share price"},{"amount":"$2.03","context":"May 1, 2025 closing price"},{"amount":"$78.00","context":"Class Period high"},{"amount":"$20.00","context":"post-peak collapse price"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by SueWallSt (Levi & Korsinsky). It is marketing material for a class action, not an issuer disclosure. Per guardrails, these are scored as low-impact noise (score 1) unless a class is certified or a major settlement is announced."},"tickerRelevance":{"others":[],"primary":"RGC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"context":"RGC is a known meme/manipulation target, but the release itself is low-value marketing noise.","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt (Levi & Korsinsky) issued a press release soliciting shareholders of Regencell Bioscience Holdings (RGC) to join a class action lawsuit.\n\nThe firm alleges that RGC's $14 billion market valuation was inflated by undisclosed market manipulation, despite the company having zero revenue and only 12 employees.\n\nThe release highlights a DOJ subpoena regarding trading activity and a subsequent 18.56% stock drop, urging investors to contact the firm by the June 23, 2026 lead plaintiff deadline.","key_figures":{"customDimensions":{"surge_pct":"48,650%","market_cap":"$14 billion","employee_count":12,"price_drop_pct":"18.56%","price_drop_usd":"$3.09","rd_spend_annual":"$1 million","share_price_peak":"$78.00","share_price_close":"$13.56"}},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at Levi & Korsinsky"}],"products":[],"companies":[{"name":"Regencell Bioscience Holdings Limited","ticker":"RGC","relationship":"defendant"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"U.S. Department of Justice","relationship":"regulator"}],"dollarAmounts":[{"amount":"$14 billion","context":"market capitalization"},{"amount":"$1 million","context":"annual R&D spend"},{"amount":"$3.09","context":"share price drop"},{"amount":"$13.56","context":"closing share price"},{"amount":"$0.30","context":"pre-surge share price"},{"amount":"$2.03","context":"May 1, 2025 closing price"},{"amount":"$78.00","context":"Class Period high"},{"amount":"$20.00","context":"post-peak collapse price"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-21T13:06:45.155Z","global_importance":15,"audience_relevance":10,"importance_components":{"context":"RGC is a known meme/manipulation target, but the release itself is low-value marketing noise.","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":28334,"modelName":"george-droid-qwen-72b"}}